imiquimod has been researched along with naphthoquinones in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA | 1 |
| Choi, EJ; Hong, MP; Kie, JH; Kim, HR; Lee, A; Lee, HK; Lim, W; Moon, BI; Seoh, JY | 1 |
| Di, T; Li, P; Lin, Y; Liu, X; Wang, Y; Zeng, Z; Zhang, L; Zhao, J | 1 |
| Gao, XH; Geng, L; Lan, XO; Liu, XY; Xu, YY; Yu, YJ; Zhang, XL | 1 |
| Gao, XH; Geng, L; Guo, H; Lan, XO; Qi, RQ; Wang, HX; Xu, YY; Yang, Y; Yu, YJ | 1 |
| Cha, X; Chen, Y; Lai, B; Tao, T; Wang, J; Wang, W; Xiao, W | 1 |
| Funatsu, T; Harada, Y; Ikoma, K; Matsui, Y; Misawa, T; Nakayama, A; Nishida, S; Noguchi, Y; Pan, Y; Saitoh, T; Shirasaki, Y; Sunazuka, T; Takahama, M; Takemura, N; Taura, M | 1 |
1 review(s) available for imiquimod and naphthoquinones
| Article | Year |
|---|---|
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption | 2012 |
6 other study(ies) available for imiquimod and naphthoquinones
| Article | Year |
|---|---|
Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function.
Topics: Acetylcysteine; Aminoquinolines; Animals; Dermatitis; Disease Progression; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Hyperbaric Oxygenation; Imiquimod; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred C57BL; NADPH Oxidases; Naphthoquinones; Psoriasis; Reactive Oxygen Species; T-Lymphocytes, Regulatory | 2014 |
Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model.
Topics: Aminoquinolines; Animals; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells; Dermatologic Agents; Disease Models, Animal; Humans; Imiquimod; Inflammation Mediators; Lymphocyte Activation; Lymphocytes; Male; Mice, Inbred BALB C; Naphthoquinones; Psoriasis; Severity of Illness Index; Skin; Time Factors | 2015 |
Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-δ upregulation.
Topics: Animals; Apoptosis; CCAAT-Enhancer-Binding Protein-delta; Cell Line; Cell Proliferation; Humans; Imiquimod; Janus Kinases; Keratinocytes; Male; Mice, Inbred BALB C; Naphthoquinones; Psoriasis; STAT3 Transcription Factor; Up-Regulation | 2019 |
Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model.
Topics: Animals; CCAAT-Enhancer-Binding Protein-delta; Cell Proliferation; Disease Models, Animal; Down-Regulation; HaCaT Cells; Humans; Imiquimod; Interleukin-17; Interleukin-6; Mice; Naphthoquinones; Psoriasis; Signal Transduction; STAT3 Transcription Factor | 2020 |
Shikonin combined with methotrexate regulate macrophage polarization to treat psoriasis.
Topics: Animals; Imiquimod; Lipopolysaccharides; Macrophages; Methotrexate; Mice; Naphthoquinones; Psoriasis | 2022 |
Nanaomycin E inhibits NLRP3 inflammasome activation by preventing mitochondrial dysfunction.
Topics: Caspase 1; Imiquimod; Inflammasomes; Interleukin-1beta; Mitochondria; Naphthoquinones; NLR Family, Pyrin Domain-Containing 3 Protein | 2022 |